Interferon α-2a therapy in 18 hemangioblastomas

Clinical Cancer Research

Volumn 7, Issue 3, 2001, Pages 510-516

  Niemela M ^a   Maenpaa H ^a   Salven, P ^a   Summanen, P ^a   Poussa, K ^a   Laatikainen, L ^a   Jaaskelainen J ^a   Joensuu, H ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ERYTHROPOIETIN; RECOMBINANT ALPHA2A INTERFERON; ROCERON A; VASCULOTROPIN;

ADULT; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM TUMOR; DRUG EFFICACY; FEMALE; HEMANGIOBLASTOMA; HUMAN; KIDNEY TUMOR; MALE; PANCREAS CYST; PRIORITY JOURNAL; RETINA TUMOR; VON HIPPEL LINDAU DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ERYTHROPOIETIN; FEMALE; HEMANGIOBLASTOMA; HUMANS; INTERFERON ALFA-2A; LYMPHOKINES; MALE; MIDDLE AGED; RETINAL NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034900366     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Human cancer syndromes: Clues to the origin and nature of cancer
2. Von Hippel-Lindau disease: A genetic study
3. Von Hippel-Lindau syndrome
4. Haemangioblastoma, haemangioblastomatosis, and von Hippel-Lindau disease
5. Identification of the von Hippel-Lindau disease tumor suppressor gene
6. Functions of the von Hippel-Lindau tumour suppressor protein
7. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
8. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumour suppressor gene product
9. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas
10. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau suppressor gene
11. Clinical features and natural history of von Hippel-Lindau disease
12. Long-term prognosis of heamangioblastoma of the CNS: Impact of von Hippel-Lindau disease
13. Hemangioblastomas: Clinical and histopathological factors correlated with recurrence
14. Von Hippel-Lindau disease and capillary hemangioblastoma
15. Erythropoietin in capillary hemangioblastoma. An immunohistochemical study
16. Central nervous system hemangioblastoma: A clinical and genetic study of 52 cases
17. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar hemangioblastoma and renal cell carcinoma
18. Hemangioblastomas of the central nervous system
19. L'hemangioblastome existe-t-il en dehors de la maladie de von Hippel-Lindau?
20. Von Hippel-Lindau disease
21. Hemangioblastoma of the central nervous system in von Hippel-Lindau disease
22. The eye in von Hippel-Lindau disease. Long-term follow-up of screening and treatment. Recommendations
23. Hemangioblastomas of the retina: Impact of von Hippel-Lindau disease
24. Preoperative embolization of brain and spinal hemangioblastomas
25. Gamma knife radiosurgery in 11 hemangioblastomas
26. Regimens with or without interferon-α as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials
27. Inhibition of angiogenesis by interferons: Effects on tumor and lymphocyte-induced vascular responses
28. Hairy cell leukemia: A clinical review based on 725 cases of the Italian cooperative group (ICGHCL)
29. Interferon α-2a therapy for life-threatening hemangiomas of infancy
30. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
31. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
32. Efficacy of recombinant interferon-α (rIFN-α) in polycythaemia vera: A study of 17 patients and an analysis of published data
33. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
34. Reporting results of cancer treatment
35. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
36. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumours in mice
37. Vascular endothelial growth factor
38. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: A potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy
39. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor
40. The natural history of renal lesions in von Hippel-Lindau disease: A serial CT study in 28 patients
41. Serum VEGF is often elevated in disseminated cancers
42. Von Hippel-Lindau disease: Case report of patient with spontaneous regression of a retinal angioma
43. Angiostatin: An endogenous inhibitor of angiogenesis and of tumor growth
44. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth